Study title: Open clinical study to evaluate persistence of antibodies induced by a primary vaccination course using SmithKline Beecham Biologicals¿ Hib vaccine mixed with SmithKline Beecham Biologicals' DTPa vaccine, and to assess immunogenicity and reactogenicity of a booster dose of the same vaccines at 15-20 months of age (referred to in this report as Hib-21).
| Type of medicine: Non-centrally authorised vaccines | |||||
| Therapeutic area: Bacterial Infections and Mycoses [01] | |||||
| Brands: Please see report, Please see report, Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: Haemophilus influenzae type b capsular polysaccharide (PRP) conjugated to tetanus toxoid (TT) | |||||
| ATC code: J07AG01/ J07AG51 | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: 208108/021 | |||||
| EudraCT number: | |||||
| Scope of study: CLINICAL | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | Y | - | - | |